Hormonal
Aging is associated with reduced SIRT1 activity, which leads to decreased pVHL levels and subsequent stabilization of HIF-1α, resulting in impaired mitochondrial biogenesis and functional decline.
As you age, your body's ability to regulate oxygen-sensing pathways (specifically the SIRT1-pVHL-HIF-1α axis) changes, leading to reduced mitochondrial efficiency. While you cannot directly 'dose' this mechanism, understanding that this is a natural part of aging helps contextualize fatigue and metabolic changes. Interventions like caloric restriction or compounds like resveratrol are mentioned as potential ways to support SIRT1 activity, but the primary takeaway is that this is a complex, multi-factorial biological process.
Aging-associated reductions in the nuclear energy state and NAD+ levels decrease SIRT1 activity, resulting in diminished pVHL levels and the stabilization of HIF-1α (Fig. 3).
Why this rating
The paper is a review citing multiple studies (refs 79-86) establishing the SIRT1-pVHL-HIF-1α axis.
Source
Hypoxia and aging
Eui‐Ju Yeo · Experimental & Molecular Medicine · 2019
DOI 10.1038/s12276-019-0233-3
More from this paper
- Intermittent hypoxia (such as from Obstructive Sleep Apnea) activates NFκB and inflammatory mediators like TNF-α without sufficiently stabilizing HIF-1α, leading to chronic inflammation and disease progression.Good
- Activation of AMPK during hypoxia and aging promotes mitochondrial biogenesis via PGC-1α and inhibits chronic inflammation by suppressing NFκB, thereby extending healthspan.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →